PMID- 15451048
OWN - NLM
STAT- MEDLINE
DCOM- 20050210
LR  - 20131121
IS  - 0892-0362 (Print)
IS  - 0892-0362 (Linking)
VI  - 26
IP  - 6
DP  - 2004 Nov-Dec
TI  - Absorption and clearance of +/-3,4-methylenedioxymethamphetamine from the plasma 
      of neonatal rats.
PG  - 849-56
AB  - A limited number of studies exist describing the effects of 
      +/-3,4-methylenedioxymethamphetamine (MDMA) during perinatal development, 
      although the number of MDMA users has increased dramatically, and this increase 
      is greatest in people of child-bearing age. Previous experimental studies show 
      that exposure to MDMA during part of the third trimester-equivalent (postnatal 
      days P1-20 in rats) cause two distinct types of learning and memory deficits 
      (sequential and spatial) if exposed on P11-20, but not if exposure occurs on 
      P1-10. In the present study, we examined differences in the ability of neonatal 
      rats to eliminate MDMA. Rat offspring were given a single dose of 20 mg/kg MDMA 
      on either P1 or 11, and plasma was collected at 1 of 10 time points during a 10-h 
      period. MDMA concentrations were assessed by liquid chromatography/mass 
      spectrometry (LC/MS). Indices of absorption did not differ as a function of 
      exposure age. Exposure age differences in the clearance rate and half-life of 
      MDMA were observed, such that the P1-treated animals had a significantly more 
      rapid clearance and a shorter half-life than P11-treated animals did. These 
      changes are in the same direction as the behavioral differences reported 
      previously between P1-10 and P11-20 MDMA exposure groups. However, the 
      pharmacokinetic differences were not commensurate with the behavioral changes in 
      that the clearance differences at the two ages are quantitative whereas the 
      behavioral differences were qualitative (no effects from P1-10 exposure and large 
      effects from P11-20). Although the data do not suggest a mechanism for the 
      learning deficits, they indicate that pharmacokinetic differences may contribute 
      to the effects seen when exposure is begun on P11.
FAU - Williams, Michael T
AU  - Williams MT
AD  - Child Neurology, Cincinnati Children's Research Foundation and University of 
      Cincinnati College of Medicine, OH, USA.
FAU - Brown, Carrie A
AU  - Brown CA
FAU - Skelton, Matthew R
AU  - Skelton MR
FAU - Vinks, Alexander A
AU  - Vinks AA
FAU - Vorhees, Charles V
AU  - Vorhees CV
LA  - eng
GR  - DA11902/DA/NIDA NIH HHS/United States
GR  - DA14269/DA/NIDA NIH HHS/United States
GR  - ES07051/ES/NIEHS NIH HHS/United States
GR  - N01 DA-6-7052/DA/NIDA NIH HHS/United States
PT  - Journal Article
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - Neurotoxicol Teratol
JT  - Neurotoxicology and teratology
JID - 8709538
RN  - KE1SEN21RM (N-Methyl-3,4-methylenedioxyamphetamine)
SB  - IM
MH  - Age Factors
MH  - Animals
MH  - Animals, Newborn
MH  - Area Under Curve
MH  - Male
MH  - Metabolic Clearance Rate/physiology
MH  - N-Methyl-3,4-methylenedioxyamphetamine/*blood/*pharmacokinetics
MH  - Rats
MH  - Rats, Sprague-Dawley
EDAT- 2004/09/29 05:00
MHDA- 2005/02/11 09:00
CRDT- 2004/09/29 05:00
PHST- 2003/03/21 00:00 [received]
PHST- 2004/08/02 00:00 [accepted]
PHST- 2004/09/29 05:00 [pubmed]
PHST- 2005/02/11 09:00 [medline]
PHST- 2004/09/29 05:00 [entrez]
AID - S0892-0362(04)00116-3 [pii]
AID - 10.1016/j.ntt.2004.08.002 [doi]
PST - ppublish
SO  - Neurotoxicol Teratol. 2004 Nov-Dec;26(6):849-56. doi: 10.1016/j.ntt.2004.08.002.